Vistin Pharma - Capital/Financing Update 2019

Vistin Pharma ASA: Volume of oil derivative contracts reduced

Oslo, Norway, 14 November 2019

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN), announces that the company has

closed the derivative contract for 15,000 metric tons (MT) of the spread between

ICE low sulphur gasoil and Sing380 expiring in December 2019. The position was

closed at USD 364.25/MT, and resulted in a realised gain of approximately NOK

2.6 million. The spread at the contract date and 30 September 2019 was USD

345.10/MT and USD 352.80/MT respectively. Following this transaction Vistin

Pharma has a total contract volume of 135,000MT outstanding. As previously

communicated, any reduction in the volumes outstanding will be subsequently

announced.

*****

For further information, please contact:

Gunnar Manum

CFO

+47 95 17 91 90

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

About Vistin Pharma | www.vistin.com

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin

Hydrochloride (API). The Metformin is also available as Direct Compressible

lubricated granules. As a solely dedicated European Metformin producer, Vistin

Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin

Pharma is headquartered in Oslo, Norway, and has highly qualified employees and

a dedicated manufacturing facility in Kragerø.

AI assistant